This work is licensed under the Creative Commons Attribution 4.0 International License.
Lu T, Yang X, Huang Y, Zhao M, Li M, Ma K, et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res 2019; 11: 943–53. doi: 10.2147/CMAR.S187317LuTYangXHuangYZhaoMLiMMaKTrends in the incidence, treatment, and survival of patients with lung cancer in the last four decades2019119435310.2147/CMAR.S187317Open DOISearch in Google Scholar
Cancer in Slovenia 2019. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Slovenian Cancer Registry; 2022.LjubljanaInstitute of Oncology Ljubljana, Epidemiology and Cancer Registry, Slovenian Cancer Registry2022Search in Google Scholar
Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28: iv1–21. doi: 10.1093/annonc/mdx222PostmusPEKerrKMOudkerkMSenanSWallerDAVansteenkisteJEarly and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up201728iv12110.1093/annonc/mdx222Open DOISearch in Google Scholar
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) v 1, 2003. [cited 2022 Dec 28]. Available at: https://www.nccn.org/login?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.EttingerDSWoodDEAisnerDLAkerleyWBaumanJRBharatA[cited 2022 Dec 28]. Available at: https://www.nccn.org/login?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.Search in Google Scholar
Guckenberger M, Andratschke N, Alheit H, Holy R, Moustakis C, Nestle U, et al. Definition of stereotactic body radiotherapy. Strahlenther Onkol 2014; 190: 26–33. doi: 10.1007/s00066-013-0450-yGuckenbergerMAndratschkeNAlheitHHolyRMoustakisCNestleUDefinition of stereotactic body radiotherapy2014190263310.1007/s00066-013-0450-yOpen DOISearch in Google Scholar
Guckenberger M, Andratschke N, Dieckmann K, Hoogeman MS, Hoyer M, Hurkmans C, et al. ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. Radiother Oncol 2017; 124: 11–7. doi: 10.1016/j.radonc.2017.05.012GuckenbergerMAndratschkeNDieckmannKHoogemanMSHoyerMHurkmansCESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer201712411710.1016/j.radonc.2017.05.012Open DOISearch in Google Scholar
Timmerman RD, Paulus R, Pass HI, Gore EM, Edelman MJ, Galvin J, et al. Stereotactic body radiation therapy for operable early-stage lung cancer findings from the NRG oncology RTOG 0618 trial. JAMA Oncol 2018; 4: 1263–6. doi: 10.1001/jamaoncol.2018.1251TimmermanRDPaulusRPassHIGoreEMEdelmanMJGalvinJStereotactic body radiation therapy for operable early-stage lung cancer findings from the NRG oncology RTOG 0618 trial201841263610.1001/jamaoncol.2018.1251Open DOISearch in Google Scholar
Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 2015; 16: 630–7. doi: 10.1016/S1470-2045(15)70168-3ChangJYSenanSPaulMAMehranRJLouieAVBalterPStereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials201516630710.1016/S1470-2045(15)70168-3Open DOISearch in Google Scholar
Chang JY, Mehran RJ, Feng L, Verma V, Liao Z, Welsh JW, et al. Stereotactic ablative radiotherapy for operable stage I non-small cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol 2021; 22: 1448–57. doi: 10.1016/S1470-2045(21)00401-0ChangJYMehranRJFengLVermaVLiaoZWelshJWStereotactic ablative radiotherapy for operable stage I non-small cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery20212214485710.1016/S1470-2045(21)00401-0Open DOISearch in Google Scholar
JoLT-Ca sublobar resection (SR) versus stereotactic ablative radiotherapy (SAbR) for lung cancer (STABLE-MATES). Clinical-TrialsGov 2015. [cited 2022 Dec 28]. Available at: https://clinicaltrials.gov/ct2/show/NCT02468024JoLT-Ca sublobar resection (SR) versus stereotactic ablative radiotherapy (SAbR) for lung cancer (STABLE-MATES)2015[cited 2022 Dec 28]. Available at: https://clinicaltrials.gov/ct2/show/NCT02468024Search in Google Scholar
Veterans affairs lung cancer surgery or stereotactic radiotherapy (VALOR). ClinicalTrialsGov 2016. [cited 2022 Dec 28]. Available at: https://clinicaltrials.gov/ct2/show/NCT02984761Veterans affairs lung cancer surgery or stereotactic radiotherapy (VALOR)2016[cited 2022 Dec 28]. Available at: https://clinicaltrials.gov/ct2/show/NCT02984761Search in Google Scholar
Nyman J, Hallqvist A, Lund JA, Brustugun OT, Bergman B, Bergström P, et al. SPACE – a randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. Radiother Oncol 2016; 121: 1–8. doi: 10.1016/j.radonc.2016.08.015NymanJHallqvistALundJABrustugunOTBergmanBBergströmPSPACE – a randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC20161211810.1016/j.radonc.2016.08.015Open DOISearch in Google Scholar
Swaminath A, Parpia S, Wierzbicki M, Kundapur V, Faria SL, Okawara G, et al. LUSTRE: a phase III randomized trial of stereotactic body radiotherapy (SBRT) vs. conventionally hypofractionated radiotherapy (CRT) for medically inoperable stage I non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 2022; 114: 1061–2. doi: 10.1016/j.ijrobp.2022.09.009SwaminathAParpiaSWierzbickiMKundapurVFariaSLOkawaraGLUSTRE: a phase III randomized trial of stereotactic body radiotherapy (SBRT) vs. conventionally hypofractionated radiotherapy (CRT) for medically inoperable stage I non-small cell lung cancer (NSCLC)20221141061210.1016/j.ijrobp.2022.09.009Open DOISearch in Google Scholar
Ball D, Mai GT, Vinod S, Babington S, Ruben J, Kron T, et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage I non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol 2019; 20: 494–503. doi: 10.1016/S1470-2045(18)30896-9BallDMaiGTVinodSBabingtonSRubenJKronTStereotactic ablative radiotherapy versus standard radiotherapy in stage I non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial20192049450310.1016/S1470-2045(18)30896-9Open DOISearch in Google Scholar
Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 2010; 37: 4078–101. doi: 10.1118/1.3438081BenedictSHYeniceKMFollowillDGalvinJMHinsonWKavanaghBStereotactic body radiation therapy: the report of AAPM Task Group 101201037407810110.1118/1.3438081Open DOISearch in Google Scholar
Videtic GMM, Hu C, Singh AK, Chang JY, Parker W, Olivier KR, et al. A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer: NRG Oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys 2015; 93: 757–64. doi: 10.1016/j.ijrobp.2015.07.2260VideticGMMHuCSinghAKChangJYParkerWOlivierKRA randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer: NRG Oncology RTOG 0915 (NCCTG N0927)2015937576410.1016/j.ijrobp.2015.07.2260Open DOISearch in Google Scholar
Adebahr S, Collette S, Shash E, Lambrecht M, Le Pechoux C, Faivre-Finn C, et al. LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective. Br J Radiol 2015; 88: 20150036. doi: 10.1259/bjr.20150036AdebahrSColletteSShashELambrechtMLe PechouxCFaivre-FinnCLungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective2015882015003610.1259/bjr.20150036Open DOISearch in Google Scholar
Sahgal A, Chang JH, Ma L, Marks LB, Milano MT, Medin P, et al. Spinal cord dose tolerance to stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2021; 110: 124–36. doi: 10.1016/j.ijrobp.2019.09.038SahgalAChangJHMaLMarksLBMilanoMTMedinPSpinal cord dose tolerance to stereotactic body radiotherapy20211101243610.1016/j.ijrobp.2019.09.038Open DOISearch in Google Scholar
National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v5. 2021. [cited 2022 Dec 29]. Available at: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50National Cancer Institute2021[cited 2022 Dec 29]. Available at: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50Search in Google Scholar
Peterlin P, Stanič K, Méndez I, Strojnik A. Treating lung cancer with dynamic conformal arc therapy: a dosimetric study. Radiat Oncol 2017; 12: 93. doi: 10.1186/s13014-017-0823-yPeterlinPStaničKMéndezIStrojnikA.Treating lung cancer with dynamic conformal arc therapy: a dosimetric study2017129310.1186/s13014-017-0823-yOpen DOISearch in Google Scholar
Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi, G, Lax I, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009; 27: 3290–6. doi: 10.1200/JCO.2008.21.5681BaumannPNymanJHoyerMWennbergBGagliardiGLaxIOutcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy2009273290610.1200/JCO.2008.21.5681Open DOISearch in Google Scholar
Singh AK, Gomez-Suescun JA, Stephans KL, Bogart JA, Hermann GM, Tian L, et al. One versus three fractions of stereotactic body radiation therapy for peripheral stage I to II non-small cell lung cancer: a randomized, multi-institution, phase 2 trial. Int J Radiat Oncol Biol Phys 2019; 105: 752–9. doi: 10.1016/j.ijrobp.2019.08.019SinghAKGomez-SuescunJAStephansKLBogartJAHermannGMTianLOne versus three fractions of stereotactic body radiation therapy for peripheral stage I to II non-small cell lung cancer: a randomized, multi-institution, phase 2 trial2019105752910.1016/j.ijrobp.2019.08.019Open DOISearch in Google Scholar
Videtic GM, Paulus R, Singh AK, Chang JY, Parker W, Olivier KR, et al. Long-term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): a randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2019; 103: 1077–84. doi: 10.1016/j.ijrobp.2018.11.051VideticGMPaulusRSinghAKChangJYParkerWOlivierKRLong-term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): a randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer201910310778410.1016/j.ijrobp.2018.11.051Open DOISearch in Google Scholar
Timmerman RD, Hu C, Michalski JM, Bradley JC, Galvin J, Johnstone DW, et al. Long-term results of stereotactic body radiation therapy in medically inoperable stage I non-small cell lung cancer. JAMA Oncol 2018; 4: 1287–8. doi: 10.1001/jamaoncol.2018.1258TimmermanRDHuCMichalskiJMBradleyJCGalvinJJohnstoneDWLong-term results of stereotactic body radiation therapy in medically inoperable stage I non-small cell lung cancer201841287810.1001/jamaoncol.2018.1258Open DOISearch in Google Scholar
Taremi M, Hope A, Dahele M, Pearson S, Fung S, Purdie T, et al. Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients. Int J Radiat Oncol Biol Phys 2012; 82: 967–73. doi: 10.1016/j.ijrobp.2010.12.039TaremiMHopeADaheleMPearsonSFungSPurdieTStereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients2012829677310.1016/j.ijrobp.2010.12.039Open DOISearch in Google Scholar
Singh D, Chen Y, Hare MZ, Usuki KY, Zhang H, Lundquist T, et al. Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung. J Thorac Dis 2014; 6: 369–74. doi: 10.3978/j.issn.2072-1439.2013.12.03SinghDChenYHareMZUsukiKYZhangHLundquistTLocal control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung201463697410.3978/j.issn.2072-1439.2013.12.03Open DOISearch in Google Scholar
Abreu CECV, Moraes FY, Miranda FA, Siqueira GSM, Gadia R, Haddad CK, et al. Stereotactic body radiation therapy for biopsy-proven primary non-small-cell lung cancer: experience of patients with inoperable cancer at a single brazilian institution. J Glob Oncol 2018; 4: 1–8. doi: 10.1200/JGO.18.00020AbreuCECVMoraesFYMirandaFASiqueiraGSMGadiaRHaddadCKStereotactic body radiation therapy for biopsy-proven primary non-small-cell lung cancer: experience of patients with inoperable cancer at a single brazilian institution201841810.1200/JGO.18.00020Open DOISearch in Google Scholar
Doupnik NP, Hirmiz K, Hussein AA, Agapito J, Pan M. Early-stage non-small cell lung cancer stereotactic body radiation therapy outcomes in a single institution. Cureus 2022; 14: e21878. doi: 10.7759/cureus.21878DoupnikNPHirmizKHusseinAAAgapitoJPanM.Early-stage non-small cell lung cancer stereotactic body radiation therapy outcomes in a single institution202214e2187810.7759/cureus.21878Open DOISearch in Google Scholar
Lackey A, Donington JS. Surgical management of lung cancer. Semin Intervent Radiol 2013; 30: 133–40. doi: 10.1055/s-0033-1342954LackeyADoningtonJS.Surgical management of lung cancer2013301334010.1055/s-0033-1342954Open DOISearch in Google Scholar
Zadnik V, Žagar T, Tomšič S, Lokar K, Duratović Konjević A, Zakotnik B. Survival of cancer patients, diagnosed in 1997–2016 in Slovenia. Ljubljana: Institute of Oncology Ljubljana; 2021.ZadnikVŽagarTTomšičSLokarKDuratović KonjevićAZakotnikB.LjubljanaInstitute of Oncology Ljubljana2021Search in Google Scholar
Bitenc M, Cufer T, Kern I, Miklavcic M, Petrovic S, Groznik v, Sadikov A. Real-life long-term outcomes of upfront surgery in patients with resectable stage I-IIIA non-small cell lung cancer. Radiol Oncol 2022; 56: 346–54. doi: 10.2478/raon-2022-0030BitencMCuferTKernIMiklavcicMPetrovicSGroznikvSadikovA.Real-life long-term outcomes of upfront surgery in patients with resectable stage I-IIIA non-small cell lung cancer2022563465410.2478/raon-2022-0030Open DOISearch in Google Scholar
Mullins K. Stereotactic body radiotherapy for early-stage non-small cell lung cancer: when and why is it appropriate therapy? J Adv Pract Oncol 2015; 6: 351–4. doi: 10.6004/jadpro/2015.6.4.5MullinsK.Stereotactic body radiotherapy for early-stage non-small cell lung cancer: when and why is it appropriate therapy?20156351410.6004/jadpro/2015.6.4.5Open DOISearch in Google Scholar
Haasbeek CJA, Palma D, Visser O, Lagerwaard FJ, Slotman B, Senan S. Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands. Ann Oncol 2012; 23: 2743–7. doi: 10.1093/annonc/mds081HaasbeekCJAPalmaDVisserOLagerwaardFJSlotmanBSenanS.Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands2012232743710.1093/annonc/mds081Open DOISearch in Google Scholar
von Reibnitz D, Shaikh F, Wu AJ, Treharne GC, Dick-Godfrey R, Foster A, et al. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC). Acta Oncol 2018; 57: 1567–73. doi: 10.1080/0284186X.2018.1481292von ReibnitzDShaikhFWuAJTreharneGCDick-GodfreyRFosterAStereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC)20185715677310.1080/0284186X.2018.1481292Open DOISearch in Google Scholar
Ishikura S. Optimal radiotherapy for non-small-cell lung cancer: current progress and future challenges. Gen Thorac Cardiovasc Surg 2012; 60: 127–31. doi: 10.1007/s11748-011-0832-yIshikuraS.Optimal radiotherapy for non-small-cell lung cancer: current progress and future challenges2012601273110.1007/s11748-011-0832-yOpen DOISearch in Google Scholar
Wegner RE, Ahmed N, Hasan S, Schumacher LY, Van Deusen M, Colonias A. SBRT for early stage lung cancer: outcomes from biopsy-proven and empirically treated lesions. Lung Cancer Manag 2018; 7: LMT01. doi: 10.2217/lmt-2018-0006WegnerREAhmedNHasanSSchumacherLYVan DeusenMColoniasA.SBRT for early stage lung cancer: outcomes from biopsy-proven and empirically treated lesions20187LMT0110.2217/lmt-2018-0006Open DOISearch in Google Scholar
Haidar YM, Rahn DA, Nath S, Song W, Bazhenova L, Makani S, et al. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation. Ther Adv Respir Dis 2014; 8: 3–12. doi: 10.1177/1753465813512545HaidarYMRahnDANathSSongWBazhenovaLMakaniSComparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation2014831210.1177/1753465813512545Open DOISearch in Google Scholar
Hasan S, Colonias A, Mickus T, VanDeusen M, Rodney E. Wegner RE, et al. Image-based management of empiric lung stereotactic body radiotherapy (SBRT) without biopsy: predictors from a 10 year single institution experience. Thorac Cancer 2018; 9: 699–706. doi: 10.1111/1759-7714.12635HasanSColoniasAMickusTVanDeusenMRodneyEWegnerREImage-based management of empiric lung stereotactic body radiotherapy (SBRT) without biopsy: predictors from a 10 year single institution experience2018969970610.1111/1759-7714.12635Open DOISearch in Google Scholar
IJsseldijk MA, Shoni M, Siegert C, Wiering B, van Engelenburg KCA, Lebenthal A, et al. Survival after stereotactic body radiation therapy for clinically diagnosed or biopsy-proven early-stage NSCLC: a systematic review and meta-analysis. J Thorac Oncol 2019; 14: 583–95. doi: 10.1016/j.jtho.2018.12.035IJsseldijkMAShoniMSiegertCWieringBvan EngelenburgKCALebenthalASurvival after stereotactic body radiation therapy for clinically diagnosed or biopsy-proven early-stage NSCLC: a systematic review and meta-analysis2019145839510.1016/j.jtho.2018.12.035Open DOISearch in Google Scholar
Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007; 2: S94–100. doi: 10.1097/JTO.0b013e318074de34OnishiHShiratoHNagataYHiraokaMFujinoMGomiKHypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study20072S9410010.1097/JTO.0b013e318074de34Open DOISearch in Google Scholar
Zhang J, Yang F, Li B, Li H, Liu J, Huang W, et al. Which is the optimal biologically effective dose of stereotactic body radiotherapy for stage I non-small-cell lung cancer? A meta-analysis. Int J Radiat Oncol Biol Phys 2011; 81: e305–16. doi: 10.1016/j.ijrobp.2011.04.034ZhangJYangFLiBLiHLiuJHuangWWhich is the optimal biologically effective dose of stereotactic body radiotherapy for stage I non-small-cell lung cancer? A meta-analysis201181e3051610.1016/j.ijrobp.2011.04.034Open DOISearch in Google Scholar
Koshy M, Malik R, Weichselbaum RR, Sher DJ. Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2015; 91: 344–50. doi: 10.1016/j.ijrobp.2014.10.002KoshyMMalikRWeichselbaumRRSherDJ.Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small cell lung cancer2015913445010.1016/j.ijrobp.2014.10.002Open DOISearch in Google Scholar
Alite F, Stang K, Balasubramanian N, Adams W, Shaikh MP, Small C, et al. Local control dependence on consecutive vs. nonconsecutive fractionation in lung stereotactic body radiation therapy. Radiother Oncol 2016; 121: 9–14. doi: 10.1016/j.radonc.2016.07.026AliteFStangKBalasubramanianNAdamsWShaikhMPSmallCLocal control dependence on consecutive vs. nonconsecutive fractionation in lung stereotactic body radiation therapy201612191410.1016/j.radonc.2016.07.026Open DOISearch in Google Scholar
Ikawa T, Tabuchi T, Konishi K, Morimoto M, Hirata T, Kanayama N, et al. Prolonged overall treatment time negatively affects the outcomes of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: a propensity score-weighted, single-center analysis. PLoS One 2021; 16: e0253203. doi: 10.1371/journal.pone.0253203IkawaTTabuchiTKonishiKMorimotoMHirataTKanayamaNProlonged overall treatment time negatively affects the outcomes of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: a propensity score-weighted, single-center analysis202116e025320310.1371/journal.pone.0253203Open DOISearch in Google Scholar